Home » Topics » Regulatory » EMA

EMA
RSS

EMA committee issues opinion on taliglucerase alfa

June 25, 2012

Theratechnologies gives update on tesamorelin regulatory progress

June 25, 2012

European CHMP adopts opinion on teduglutide

June 25, 2012

Alexza provides update on Adasuve submissions

June 25, 2012

EMA validates MAAs for fixed-dose combination diabetes therapies

June 20, 2012

Investigational gene therapy gets orphan drug status for adrenoleukodystrophy

June 20, 2012

EMA to conduct centralized review of elvitegravir MAA

June 19, 2012

Genta reaches agreement on phase III tesetaxel trial

June 19, 2012

EMA's COMP issues opinion on Enhoxy

June 14, 2012

AR-42 gets E.U. orphan drug status for two additional indications

June 8, 2012

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...